- Previous Close
4.2700 - Open
4.2500 - Bid 4.1400 x 100
- Ask 4.5000 x 100
- Day's Range
4.2400 - 4.3738 - 52 Week Range
2.3800 - 11.9900 - Volume
5,415 - Avg. Volume
142,396 - Market Cap (intraday)
46.155M - Beta (5Y Monthly) 1.60
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6200 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.00
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
www.lanternpharma.comRecent News: LTRN
View MorePerformance Overview: LTRN
Trailing total returns as of 6/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LTRN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LTRN
View MoreValuation Measures
Market Cap
45.72M
Enterprise Value
7.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.28
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.36%
Return on Equity (ttm)
-39.70%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.53M
Diluted EPS (ttm)
-1.6200
Balance Sheet and Cash Flow
Total Cash (mrq)
38.36M
Total Debt/Equity (mrq)
0.54%
Levered Free Cash Flow (ttm)
-7.39M